{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:17:17Z","timestamp":1789697837061,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.juro.2012.07.020","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T04:35:15Z","timestamp":1348029315000},"page":"1712-1718","source":"Crossref","is-referenced-by-count":106,"title":["A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1097","volume":"188","author":[{"given":"Mark","family":"Kowalski","sequence":"first","affiliation":[{"name":"Viventia Biotechnologies Inc., Mississauga, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinthe","family":"Guindon","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Mississauga, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Brazas","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Mississauga, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Moore","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Mississauga, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyn","family":"Entwistle","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Winnipeg, Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannick","family":"Cizeau","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Winnipeg, Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.S.","family":"Jewett","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, Toronto, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen C.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Viventia Biotechnologies Inc., Winnipeg, Manitoba"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2012.07.020_bib1","author":"Montie"},{"key":"10.1016\/j.juro.2012.07.020_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00262-004-0621-x","article-title":"Immunotherapy for superficial bladder cancer","volume":"54","author":"Schenk-Braat","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2012.07.020_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.07.020_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/1097-0142(19940701)74:1<115::AID-CNCR2820740120>3.0.CO;2-R","article-title":"Carcinoma in situ of the urinary bladder","volume":"74","author":"Orozco","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2012.07.020_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2012.07.020_bib7","first-page":"2837","article-title":"A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity","volume":"9","author":"DiPaolo","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2012.07.020_bib8","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1016\/S0021-9258(19)68883-6","article-title":"Diphtheria toxin","volume":"256","author":"Oppenheimer","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.juro.2012.07.020_bib9","first-page":"313","article-title":"A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients","volume":"4","author":"Kowalski","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.juro.2012.07.020_bib10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.07.020_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.juro.2012.07.020_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.juro.2012.07.020_bib13","series-title":"Design and Analysis of Experiments for Statistical Selection, Screening, and Multiple Comparisons","author":"Bechhofer","year":"1995"},{"key":"10.1016\/j.juro.2012.07.020_bib14","first-page":"265","article-title":"Pharmacological treatments for BCG-refractory cancer of the urinary bladder","volume":"20","author":"Bronstone","year":"2008","journal-title":"Drug Benefit Trends"},{"key":"10.1016\/j.juro.2012.07.020_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000049766","article-title":"Distressful symptoms after radical cystectomy with urinary diversion for urinary bladder cancer: a Swedish population-based study","volume":"40","author":"Henningsohn","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.07.020_bib16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0090-4295(03)00765-9","article-title":"Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis","volume":"62","author":"Joudi","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2012.07.020_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.07.020_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.07.020_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2012.07.020_bib20","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette Gu\u00e9rin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712041997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712041997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2012.07.020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:59:45Z","timestamp":1651201185000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2012.07.020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1016\/j.juro.2012.07.020"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2012.07.020","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}